MDPI and ACS Style
Dimitrakopoulos, F.-I.; Nikolakopoulos, A.; Kottorou, A.; Kalofonou, F.; Liolis, E.; Frantzi, T.; Pyrousis, I.; Koutras, A.; Makatsoris, T.; Kalofonos, H.
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. Cancers 2020, 12, 1257.
https://doi.org/10.3390/cancers12051257
AMA Style
Dimitrakopoulos F-I, Nikolakopoulos A, Kottorou A, Kalofonou F, Liolis E, Frantzi T, Pyrousis I, Koutras A, Makatsoris T, Kalofonos H.
PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors. Cancers. 2020; 12(5):1257.
https://doi.org/10.3390/cancers12051257
Chicago/Turabian Style
Dimitrakopoulos, Foteinos-Ioannis, Achilleas Nikolakopoulos, Anastasia Kottorou, Fotini Kalofonou, Elias Liolis, Theodora Frantzi, Ioannis Pyrousis, Angelos Koutras, Thomas Makatsoris, and Haralabos Kalofonos.
2020. "PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors" Cancers 12, no. 5: 1257.
https://doi.org/10.3390/cancers12051257
